India’s pharmaceutical industry is no longer just the world’s low-cost supplier of generic medicines. It is steadily building scale, widening its global presence and moving into more complex segments, supported by policy momentum and growing investor confidence.
The numbers underline that shift. Pharmaceutical exports reached US$ 30.5 billion in 2024–25, nearly 16 times higher than US$ 1.9 billion in 2000–01. The domestic market, currently valued at US$ 60 billion, is projected to grow to US$ 130 billion by 2030. The sector’s annual turnover stood at ₹4.72 lakh crore in FY25, reflecting its rising contribution to the economy.
India is the third largest pharmaceutical producer globally by volume and ranks 11th by value. Its products are now exported to 191 countries, with a significant share going to highly regulated markets such as the United States and Europe. This level of access signals a clear shift in perception. Indian medicines are not only affordable but increasingly trusted.
A global supplier built on cost and credibility
India’s reputation as the “pharmacy of the world” rests on its strength in generic medicines. The country accounts for about 20 per cent of global supply and produces nearly 60,000 generic brands across multiple therapeutic categories.
Its role is also critical in global vaccination programmes. Indian manufacturers supply around 60 per cent of vaccines procured by UNICEF and meet a substantial share of global demand for DPT, BCG and measles vaccines. This makes India central to public health delivery far beyond its borders.
The scale of the industry is supported by more than 3,000 companies and over 10,500 manufacturing units. India also has the largest number of USFDA-approved plants outside the United States, reinforcing confidence in its regulatory standards. Around 500 manufacturers produce active pharmaceutical ingredients, contributing roughly 8 per cent to the global API market.
Exports grow, markets widen
Exports continue to drive growth. Nearly half of India’s pharmaceutical exports are directed towards regulated markets, while companies are expanding into emerging regions such as Brazil, Saudi Arabia, Nigeria and Mexico. This diversification is helping reduce dependence on specific geographies and manage trade-related risks.
Monthly trends reflect steady momentum, with exports rising from US$ 2.59 billion in January 2025 to US$ 2.66 billion in January 2026. Medical device exports are also gaining ground, increasing from US$ 2.5 billion in 2020–21 to US$ 4.1 billion in 2024–25.
Foreign investment remains strong. The sector attracted ₹13,193 crore in FDI between April and September 2025–26, highlighting sustained global interest in India’s manufacturing base and regulatory framework.
Trade deals and policy push
Recent trade agreements are expected to strengthen India’s position further. The free trade agreement with the European Union opens access to a market valued at over US$ 572 billion. The agreement with the United Kingdom provides duty-free access across several pharmaceutical categories, while the pact with New Zealand expands opportunities across multiple tariff lines.
On the domestic front, Production-Linked Incentive schemes are helping boost manufacturing capacity and reduce import dependence. These initiatives have already prevented imports worth ₹3,591 crore and attracted investments exceeding initial targets. The pharmaceutical PLI scheme alone has drawn investments of over ₹40,000 crore, along with significant gains in sales, exports and employment.
Moving beyond volume
There are early signs of a shift towards higher-value segments. Investments in bulk drug parks and medical device parks are improving infrastructure and lowering production costs. Research initiatives are also encouraging collaboration between industry and academia, pushing the sector beyond its traditional focus on generics.
At the same time, access to affordable medicines remains central. Under the Jan Aushadhi scheme, more than 18,600 centres are operational, offering low-cost medicines and reducing the financial burden on households.
Yet, the sector’s dependence on imported raw materials in certain segments continues to be a structural challenge, underlining the need for deeper domestic capacity.
The next phase
The proposed ‘Biopharma Shakti’ initiative signals a move towards more complex and high-value products such as biologics and biosimilars. With an outlay of ₹10,000 crore, the programme aims to strengthen clinical research infrastructure and build a more advanced pharmaceutical ecosystem.
This growth is supported by a regulatory framework that focuses on quality, safety and pricing oversight. Institutions such as the CDSCO and NPPA continue to ensure that expansion does not come at the cost of standards or accessibility.
India’s pharmaceutical sector is evolving beyond its identity as a low-cost producer. It is becoming a more balanced industry, combining scale with credibility and gradually moving into advanced areas of drug manufacturing. If current trends hold, India will not only remain a key supplier of medicines but also play a larger role in shaping how affordable healthcare is delivered worldwide.
